DE4205931A1 - Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth - Google Patents

Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth

Info

Publication number
DE4205931A1
DE4205931A1 DE19924205931 DE4205931A DE4205931A1 DE 4205931 A1 DE4205931 A1 DE 4205931A1 DE 19924205931 DE19924205931 DE 19924205931 DE 4205931 A DE4205931 A DE 4205931A DE 4205931 A1 DE4205931 A1 DE 4205931A1
Authority
DE
Germany
Prior art keywords
arginine hydrochloride
hair
soln
electrolyte concentrate
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19924205931
Other languages
German (de)
Inventor
Des Erfinders Auf Nennung Verzicht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAINDOK FRIEDRICH 4712 WERNE DE
Original Assignee
MAINDOK FRIEDRICH 4712 WERNE DE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAINDOK FRIEDRICH 4712 WERNE DE filed Critical MAINDOK FRIEDRICH 4712 WERNE DE
Priority to DE19924205931 priority Critical patent/DE4205931A1/en
Publication of DE4205931A1 publication Critical patent/DE4205931A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Abstract

The standard dose of two ml of electrolyte concentrate arginine hydrochloride with eight ml of cooking salt soln. is either injected in the buttocks or directly into the skin of the scalp. The usage of the formula is over a period of approx. three months, two to three times per week, but according to individual needs the dosage and compsn. can be varied. USE/ADVANTAGE - To combat hair fall-out and promote hair growth.

Description

Die Erfindung befaßt sich mit der Möglichkeit Haarausfall zu verhindern und den Haarwuchs zu fördern. Dies bezieht sich insbesondere auch auf sogenannten erblichen Haarausfall. Das Medikament "Elektrolytkonzentrat Argininhydrochlorid pfrimmer" war bisher auf andere Anwendungsgebiete ausgerichtet. Die Erfindung läßt dieses Medikament jedoch ganz speziell für den soeben beschriebenen Bereich der Verhinderung des Haarausfalles und der Förderung und Neubildung von Haarwuchs wirksam sein.The invention is concerned with the possibility of hair loss prevent and promote hair growth. This relates especially on so-called hereditary hair loss. The Drug "electrolyte concentrate arginine hydrochloride pfrimmer" was previously focused on other areas of application. The invention leaves this medication, however, especially for the just described area of prevention of hair loss and the Promotion and re-formation of hair growth can be effective.

Die Arzneimittelinfusionslösung Argininhydrochlorid wird nach einer bestimmten Dosierung mit einer Kochsalzlösung gemischt. So werden zwei Milliliter Argininhydrochlorid mit acht Milliliter Kochsalzlösung in der Regel gemischt und über das Gesäß oder die Kopfhaut injiziert. Die Anwendung kann dementsprechend individuell den Bedürfnissen des Patienten angepaßt werden. Sie kann also entweder über das Gesäß oder die Kopfhaut erfolgen. Die Anwendungsdauer erfolgt über einen längeren Zeitraum von ca. 3 Monaten, 2-3 Mal wöchentlich. Je nach dem individuellen Befund kann die Dosierung und Zusammensetzung zwischen den Beigaben Argininhydrochlorid und Kochsalzlösung geändert werden.The drug infusion solution arginine hydrochloride is after a certain dosage mixed with a saline solution. So are two milliliters of arginine hydrochloride with eight milliliters Saline usually mixed and over the buttocks or the Scalp injected. The application can be customized accordingly be adapted to the needs of the patient. So you can either through the buttocks or the scalp. The The duration of use is over a longer period of approx. 3 Months, 2-3 times a week. Depending on the individual findings can the dosage and composition between the additions Arginine hydrochloride and saline are changed.

Nebenwirkungen sind bislang nicht bekannt. Insoweit verbleibt es bei den besonderen Hinweisen des Herstellers der Lösung Argininhydrochlorid, wonach Kontrollen des Serum-Tonogramms und des Säure-Basen-Haushaltes erforderlich sind. Außerdem ist Vorsicht bei Hyperchlorämie geboten. Es sollen nur klare Lösungen in unversehrten Behältnissen verwendet werden. Außerdem soll das Präparat nicht angewendet werden bei Azidosen, es sei denn, daß der Arzt es anders verordnet hat.No side effects are known so far. So far it remains with the special instructions of the manufacturer of the solution Arginine hydrochloride, after which controls the serum tonogram and of the acid-base balance are required. Besides, is Beware of hyperchloremia. There are only supposed to be clear solutions can be used in undamaged containers. In addition, that should The preparation should not be used in cases of acidosis unless the doctor prescribed otherwise.

Der Erfinder geht davon aus, daß selbst abgestorbene Haarwurzeln bei ordnungsgemäßer Anwendung wie beschrieben wieder aktiv werden und sich Haare bilden.The inventor assumes that even dead hair roots reactivate as described if used correctly and hair is formed.

Claims (1)

Mit der Erfindung soll die Verwendung der Infusionslösung Elektrolytkonzentrat Argininhydrochlorid pfrimmer zur Bekämpfung des Haarausfalls und zur Anwendung für die Haarwuchsförderung sowie der Bildung neuer Haare auf abgestorbenen Wurzeln unter Patentschutz gestellt werden. Hierzu gehört auch die Bekämpfung erblichen Haarausfalls.The invention is intended to use the infusion solution Control electrolyte concentrate arginine hydrochloride pfrimmer of hair loss and for use in promoting hair growth and the formation of new hair on dead roots underneath Patent protection will be provided. Combating is also part of this hereditary hair loss.
DE19924205931 1992-02-20 1992-02-27 Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth Ceased DE4205931A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19924205931 DE4205931A1 (en) 1992-02-20 1992-02-27 Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4205111 1992-02-20
DE19924205931 DE4205931A1 (en) 1992-02-20 1992-02-27 Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth

Publications (1)

Publication Number Publication Date
DE4205931A1 true DE4205931A1 (en) 1993-08-26

Family

ID=25912017

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19924205931 Ceased DE4205931A1 (en) 1992-02-20 1992-02-27 Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth

Country Status (1)

Country Link
DE (1) DE4205931A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009750A1 (en) * 1992-10-30 1994-05-11 Unilever Plc Cosmetic composition
DE19520662A1 (en) * 1995-06-07 1996-12-12 Beiersdorf Ag Treatment for dandruff and hair

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2609393A1 (en) * 1988-02-23 1988-07-15 Serobiologiques Lab Sa Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2609393A1 (en) * 1988-02-23 1988-07-15 Serobiologiques Lab Sa Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Derwent-Ref.: 04620 K/03 *
Derwent-Ref.: 87-253862/36 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009750A1 (en) * 1992-10-30 1994-05-11 Unilever Plc Cosmetic composition
DE19520662A1 (en) * 1995-06-07 1996-12-12 Beiersdorf Ag Treatment for dandruff and hair

Similar Documents

Publication Publication Date Title
DE3528979C2 (en)
Hodapp et al. The effect of topical clonidine on intraocular pressure
DE60126265T2 (en) Composition consisting of phentolamine mesylate and their use
EP1140139B2 (en) Use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
MY102378A (en) Transdermal delivery system.
ATE84968T1 (en) MEDICATIONS CONTAINING AZELASTINE FOR NOSE AND/OR EYE USE.
IL107134A0 (en) Pharmaceutical compositions for the treatment of parkinson's disease
EP0185210B1 (en) Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis
DE10197266T5 (en) Procedures for local anesthesia and pain relief
EP2323645A1 (en) Use of low-dose local anaesthetic or derivatives thereof for therapy of chronic pain, especially migraine
US20030157185A1 (en) Topical treatment of neuropathy
Browne et al. Multicenter long‐term safety and efficacy study of vigabatrin for refractory complex partial seizures: An update
EP0002495A1 (en) Composition for use in cytostatic therapy
EP0037488A2 (en) Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes
DE2900203A1 (en) CANCER-RESISTANT AND CANCER METASTASES PREVENTING MEDICINAL PRODUCT
DE4205931A1 (en) Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth
DE1808948A1 (en) Painless injectable drug mixture
ATE159658T1 (en) METHOD AND COMPOSITIONS FOR ADMINISTRATION OF LIPOPHILIC REMEDIES IN A DOSAGE ACCORDING TO THE DESIRED EFFECT
EP1001756B1 (en) Synergistically acting compositions for selectively combating tumor tissue
Hirschmüller E. Merck und das Kokain: Zu Sigmund Freuds Kokainstudien und ihren Beziehungen zu der Darmstädter Firma
EP0018550A2 (en) Compositions for muscular disease treatment
Maier et al. Diagnostik and treatment measures in patients with sympathetically maintained pain
EP0272393A3 (en) Pharmaceutical combination
DE19610396C2 (en) Topical preparation containing dimethyl sulfoxide
DE3719367A1 (en) Use of active substances which influence the metabolism and/or the structural properties of collagen in orthodontics

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection